DeBogy Molecular
Biotechnology company developing surface-modification technologies that permanently alter material surfaces to provide contact-active antimicrobial activity. Focus areas include engineering treated surfaces for medical devices and a range of industrial and consumer materials, with preclinical data supporting efficacy and biocompatibility.
Industries
Nr. of Employees
small (1-50)
Products
Proprietary surface-modification platform
A molecular platform designed to modify material surfaces to exert contact-active antimicrobial effects across a range of substrates.
Proprietary surface-modification platform
A molecular platform designed to modify material surfaces to exert contact-active antimicrobial effects across a range of substrates.
Services
Antimicrobial surface functionalization service
Surface-treatment services and technology for imparting contact-active antimicrobial properties to a range of substrates for medical, textile and industrial applications.
Proprietary antimicrobial molecular platform
A platform of proprietary molecules intended to be immobilized on material surfaces to provide permanent biocidal activity without soluble antibiotics or toxic additives.
Technical collaboration for preclinical validation
Coordination and commissioning of external CROs for animal-model testing of surface-treated devices.
Antimicrobial surface functionalization service
Surface-treatment services and technology for imparting contact-active antimicrobial properties to a range of substrates for medical, textile and industrial applications.
Proprietary antimicrobial molecular platform
A platform of proprietary molecules intended to be immobilized on material surfaces to provide permanent biocidal activity without soluble antibiotics or toxic additives.
Technical collaboration for preclinical validation
Coordination and commissioning of external CROs for animal-model testing of surface-treated devices.
Expertise Areas
- Surface modification and functionalization
- Antimicrobial materials development
- Preclinical in vivo testing for implant-associated infection
- Biocompatibility assessment
Key Technologies
- Surface chemical functionalization
- Immobilized antimicrobial molecular agents
- Electrostatic microbial membrane disruption
- Preclinical in vivo biofilm models